Parallel Advisors’s UroGen Pharma URGN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.48K | Buy |
+400
| New | +$5.48K | ﹤0.01% | 2684 |
|
|
2022
Q2 | – | Sell |
-3,047
| Closed | -$28K | – | 3369 |
|
|
2022
Q1 | $28K | Buy |
3,047
+3,000
| +6,383% | +$27.6K | ﹤0.01% | 1556 |
|
|
2021
Q4 | $0 | Hold |
47
| – | – | ﹤0.01% | 3312 |
|
|
2021
Q3 | $1K | Hold |
47
| – | – | ﹤0.01% | 2950 |
|
|
2021
Q2 | $1K | Sell |
47
-2,000
| -98% | -$42.6K | ﹤0.01% | 2816 |
|
|
2021
Q1 | $40K | Buy |
2,047
+944
| +86% | +$18.4K | ﹤0.01% | 1273 |
|
|
2020
Q4 | $20K | Sell |
1,103
-1,444
| -57% | -$26.2K | ﹤0.01% | 1467 |
|
|
2020
Q3 | $49K | Buy |
2,547
+1,500
| +143% | +$28.9K | ﹤0.01% | 1059 |
|
|
2020
Q2 | $27K | Buy |
+1,047
| New | +$27K | ﹤0.01% | 1298 |
|
|
2020
Q1 | – | Sell |
-2,700
| Closed | -$90K | – | 2661 |
|
|
2019
Q4 | $90K | Buy |
2,700
+1,200
| +80% | +$40K | 0.01% | 817 |
|
|
2019
Q3 | $36K | Buy |
+1,500
| New | +$36K | ﹤0.01% | 1103 |
|
|
2019
Q2 | – | Sell |
-1,000
| Closed | -$37K | – | 2431 |
|
|
2019
Q1 | $37K | Hold |
1,000
| – | – | ﹤0.01% | 963 |
|
|
2018
Q4 | $43K | Buy |
1,000
+500
| +100% | +$21.5K | 0.01% | 817 |
|
|
2018
Q3 | $24K | Sell |
500
-1,500
| -75% | -$72K | ﹤0.01% | 1072 |
|
|
2018
Q2 | $99K | Buy |
2,000
+1,100
| +122% | +$54.5K | 0.01% | 542 |
|
|
2018
Q1 | $45K | Buy |
900
+100
| +13% | +$5K | 0.01% | 730 |
|
|
2017
Q4 | $30K | Hold |
800
| – | – | ﹤0.01% | 873 |
|
|
2017
Q3 | $35K | Buy |
+800
| New | +$35K | 0.01% | 799 |
|